NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis $1.25 +0.08 (+6.84%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$1.36 +0.11 (+8.80%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MaxCyte Stock (NASDAQ:MXCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MaxCyte alerts:Sign Up Key Stats Today's Range$1.14▼$1.2650-Day Range$0.96▼$1.7352-Week Range$0.64▼$1.81Volume975,795 shsAverage Volume1.47 million shsMarket Capitalization$129.06 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte serves customers and partners internationally. Its technology is used across research and clinical development, as well as in the production of cell-based medicines.AI Generated. May Contain Errors. Read More MaxCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreMXCT MarketRank™: 3.503084304315 of 5 starsMaxCyte scored higher than 70% of companies evaluated by MarketBeat, and ranked 467th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMaxCyte has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialMaxCyte has a consensus price target of $4.50, representing about 260.0% upside from its current price of $1.25.Amount of Analyst CoverageMaxCyte has only been the subject of 2 research reports in the past 90 days.Read more about MaxCyte's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.24) to ($0.17) per share.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.60% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MaxCyte has recently decreased by 13.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for MaxCyte this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added MaxCyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $121,000.00 in company stock, which represents 0.0938% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $121,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.10% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MaxCyte's insider trading history. Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXCT Stock News HeadlinesMaxCyte (MXCT) Q3 2026 Earnings Call TranscriptNovember 11, 2026 | finance.yahoo.comMaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue GuidanceNovember 10, 2026 | globenewswire.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. | Profits Run (Ad)MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue BaseNovember 10, 2026 | globenewswire.comMaxCyte (MXCT) Expected to Release Quarterly Earnings on TuesdayNovember 8, 2026 | americanbankingnews.comMaxCyte to Participate in Three Upcoming Investor ConferencesOctober 28, 2026 | globenewswire.comMaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpOctober 14, 2026 | rttnews.comMaxCyte stock rallies on initial Q3 revenue, higher FY26 outlookOctober 14, 2026 | msn.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at $1.55 on January 1st, 2026. Since then, MXCT shares have decreased by 19.4% and is now trading at $1.25. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The firm earned $8.16 million during the quarter, compared to analysts' expectations of $7.39 million. MaxCyte had a negative trailing twelve-month return on equity of 15.05% and a negative net margin of 81.40%. Read the conference call transcript. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share. Who are MaxCyte's major shareholders? Top institutional investors of MaxCyte include Liontrust Investment Partners LLP (4.69%), Brooklands Fund Management Ltd (1.52%), Marshall Wace LLP (1.51%) and Goldman Sachs Group Inc. (0.89%). Insiders that own company stock include Maher Masoud, Stanley C Erck, Douglas Doerfler, Douglas J Swirsky, William W Brooke, John Joseph Johnston, David I Sandoval, Ali Soleymannezhad, Rekha Hemrajani and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/18/20262026 Stephens Annual Investment Conference | NASH202611/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MXCT's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:MXCT CIK1287098 Webmaxcyte.com Phone(301) 517-5556Fax301-944-1703Employees91Year Founded1998Price Target and Rating Average Price Target for MaxCyte$4.50 High Price Target$5.00 Low Price Target$4.00 Potential Upside/Downside+260.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.63 million Net Margins-81.40% Pretax Margin-81.40% Return on Equity-15.05% Return on Assets-12.79% Debt Debt-to-Equity RatioN/A Current Ratio7.83 Quick Ratio7.37 Sales & Book Value Annual Sales$33.03 million Price / Sales3.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book0.86Miscellaneous Outstanding Shares103,250,000Free Float99,017,000Market Cap$129.06 million OptionableOptionable Beta1.49 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MXCT) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour secret “Black Friday” link for tradersMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.